Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | ITK | Q08881 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568592 | 0.89 | ENPP2 (0.39) | NR3C1 | |
| SCHEMBL4568099 | 0.85 | MAPT (0.43) | PARP1MRGPRX4RAB9AIDH1 | |
| SCHEMBL4568428 | 0.85 | TLR9 (0.41) | PARP1TLR9TLR8TLR7NR3C1 | |
| SCHEMBL4568117 | 0.84 | MRGPRX4 (0.49) | PARP1MRGPRX4RAB9AIDH1 | |
| SCHEMBL4568119 | 0.84 | PARP1 (0.42) | PARP1MRGPRX4RAB9AIDH1 | |
| SCHEMBL4568473 | 0.83 | TLR9 (0.41) | PARP1TLR9TLR8TLR7 | |
| SCHEMBL4568475 | 0.82 | TLR9 (0.45) | PARP1TLR9TLR8TLR7 | |
| SCHEMBL4568482 | 0.82 | PARP1 (0.46) | PARP1MRGPRX4RAB9AIDH1 | |
| SCHEMBL4568491 | 0.82 | PRMT5 (0.40) | PARP1MRGPRX4RAB9A | |
| SCHEMBL4568498 | 0.82 | TLR9 (0.43) | PARP1TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | PARP1 2429/4885TLR9 1840/4885TLR8 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.